IWR-1-endo

Catalog No.S7086 Synonyms: endo-IWR 1

For research use only.

IWR-1-endo (endo-IWR 1) is a Wnt pathway inhibitor with IC50 of 180 nM in L-cells expressing Wnt3A, induces Axin2 protein levels and promotes β-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.

IWR-1-endo Chemical Structure

CAS No. 1127442-82-3

Selleck's IWR-1-endo has been cited by 71 publications

Purity & Quality Control

Choose Selective Wnt/beta-catenin Inhibitors

Other Wnt/beta-catenin Products

Biological Activity

Description IWR-1-endo (endo-IWR 1) is a Wnt pathway inhibitor with IC50 of 180 nM in L-cells expressing Wnt3A, induces Axin2 protein levels and promotes β-catenin phosphorylation by stabilizing Axin-scaffolded destruction complexes.
Targets
Wnt [1]
(L-cells expressing Wnt3A)
180 nM
In vitro

Although both IWR-1 and XAV939 act as reversible Wnt pathway inhibitors and exhibit similar pharmacological effects both in vitro and in vivo, IWR-1 exerts its effect via interaction with Axin, while XAV939 binds TNKS directly. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BL21 (DE3) M{HYS2Z2dmO2aX;uJIF{e2G7 MXK5NEBucW6| NX71bo9xSWO2aY\peJkhd2ZiTj30[ZJucW63czDo[ZhiUGm|LYTh[4dm\CCqdX3hckBVVlONMjDlfJBz\XO|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzIDjESVMqKGOnbHzzJJV{cW6pIHLpc5RqdnmuYYTl[EBPSURtIHHzJJN2[nO2cnH0[UBi\nSncjC5NEBucW6|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiRVO1NEA:KDBwMjFOwG0v NHPCeIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKzN|MzOCd-MkKyN|M{OjB:L3G+
SW480 MkT6SpVv[3Srb36gZZN{[Xl? NXG2[YdzOjRiaILz MmmwTY5pcWKrdHnvckBw\iC2YX7rfZJie2ViaX6gbJVu[W5iU2e0PFAh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJIF5cW5{IHHmeIVzKDJ2IHjyd{BjgSCKb3XjbJN1KGS7ZT3iZZNm\CCvZYToc4QtKEWFNUCgQUAzNjVizszNMi=> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdyMUWxO{c,OjN5MEG1NVc9N2F-
HEK293T MV;GeY5kfGmxbjDhd5NigQ>? M3juT2lvcGmkaYTpc44hd2ZiYnX0ZU1k[XOnaX6t[IVx\W6mZX70JINidm:waXPhcEBYdnR|IIDheIh4[XliaX6gbJVu[W5iSFXLNlk{XCClZXzsd{BjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO|YYmsJGlEPTBiPTCwMlAzPiEQvF2u NFyyOlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG5NVU2Pyd-MkKxPVE2PTd:L3G+
SW480 MYfGeY5kfGmxbjDhd5NigQ>? M4K4RlQxKHSxIES4JIhzew>? Mme2TY5pcWKrdHnvckBw\iC2YX7rfZJie2ViaX6gbJVu[W5iU2e0PFAh[2WubIOgZZN{\XO|ZXSgZZMh\GWpcnHkZZRqd25ib3[gZoV1[SClYYTlcolvKGGodHXyJFQxKHSxIES4JIhzeyxiSVO1NEA:KDBwMkWg{txONg>? NIHY[3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ewNVUyPyd-MkO3NFE2OTd:L3G+
L-Wnt-STF NIHldI1HfW6ldHnvckBie3OjeR?= NVzqN3h3OjRiaILz NYPCUJRRUW6qaXLpeIlwdiCxZjDUUmtUNTJiaX6gcY92e2ViTD3XcpQuW1SIIHPlcIx{KGG|c3Xzd4VlKGG|IHTpd5J2eHSrb36gc4YhX262IIPp[45idGmwZzDh[pRmeiB{NDDodpMh[nlibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5MEBKSzVyIE2gNE4xPTZizszNMi=> NEjkeog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyO|c6Oid-MkS1Nlc4QTJ:L3G+
L-Wnt-STF MWXGeY5kfGmxbjDhd5NigQ>? NWKzbHZROjRiaILz Mlu4TY5pcWKrdHnvckBw\iCWTlvTMVEhcW5ibX;1d4UhVC2ZboStV3RHKGOnbHzzJIF{e2W|c3XkJIF{KGSrc4L1dJRqd25ib3[gW451KHOrZ37hcIlv\yCjZoTldkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7LDDJR|UxKD1iMD6xN|Eh|ryPLh?= MlHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mke3PVIoRjJ2NUK3O|kzRC:jPh?=
HT29 MVjGeY5kfGmxbjDhd5NigQ>? NEnU[5EzPCCqcoO= Ml6wTY5pcWKrdHnvckBw\iCZboSgd4lodmGuaX7nJIlvKGi3bXHuJGhVOjliY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBj\XSjLXPheIVvcW5vbXXkbYF1\WRiVHPmM2xm\iC2cnHud4NzcXC2aX;uZYwh[WO2aY\peJkh[W[2ZYKgNlQhcHK|IHL5JIR2[WxibIXjbYZmemG|ZTDy[ZBwenSncjDn[Y5mKGG|c3H5JJJmdGG2aY\lJJRwKGOxboTyc4wtKEmFNUCgQUAzPC52IN88UU4> NV7JdVZHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OVA1QDlpPkK0PVUxPDh7PD;hQi=>
DLD1 MnXwSpVv[3Srb36gZZN{[Xl? NF7sOlgyOCC3TR?= NIq3V5hKdmS3Y4Tpc44hd2ZiQYjpclIhcW5iaIXtZY4hTEyGMTDj[YxteyCxdnXy[ZhxemW|c3nu[{BKX1JvSWOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iV370JJBifGi5YYmgZYN1cX[rdImgZZQhOTBidV2gZpkhW1SIIILldI9zfGW{IHHzd4F6KG2ndHjv[C=> NH[4PZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGyOVE2Pid-MUmxNlUyPTZ:L3G+
HEK293 MoHmSpVv[3Srb36gZZN{[Xl? NGTtbVVFcXOybHHj[Y1mdnRib3[gTXdTNVCEIH\yc40hSXirbkKgbY4hUEWNMkmzJINmdGy|IHL5JHdme3Sncn6gZoxwfCCvZYToc4Q> MnjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 MmTQSpVv[3Srb36gZZN{[Xl? NWGwdGdmUW6qaXLpeIlwdiCxZjDBfIlvOiCycn;0[YlvKGSnZ4Lh[IF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NVjud4RkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNlUyPTZpPkG5NVI2OTV4PD;hQi=>
DLD1 M4jUe2Z2dmO2aX;uJIF{e2G7 M3n1SGlv\HWldHnvckBw\iCDeHnuNkBi[2O3bYXsZZRqd25iaX6gbJVu[W5iRFzENUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCWaIK0NUBxcG:|cHjvdplt[XSnZDDi[ZRiNWOjc3XpckBt\X[nbIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| M4LCNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUK1NVU3Lz5zOUGyOVE2PjxxYU6=
DLD1 MXzGeY5kfGmxbjDhd5NigQ>? M1fMPWlv\HWldHnvckBw\iCDeHnuNkBi[2O3bYXsZZRqd25iaX6gbJVu[W5iRFzENUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCVZYKzO{BxcG:|cHjvdplt[XSnZDDi[ZRiNWOjc3XpckBt\X[nbIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NVTJVm1tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNlUyPTZpPkG5NVI2OTV4PD;hQi=>
DLD1 M13Hc2Z2dmO2aX;uJIF{e2G7 M1\5cmRm[3KnYYPlJIlvKGKndHGtZ4F{\WmwIHHjZ5VufWyjdHnvckBqdiCqdX3hckBFVERzIHPlcIx{KGW6cILld5NqdmdiaX6gRXBEKG23dHHueC=> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF{NUG1Okc,OTlzMkWxOVY9N2F-
DLD1 NU[yd4R1TnWwY4Tpc44h[XO|YYm= NISyUJkzKGi{cx?= NH7sdGRKdmS3Y4Tpc44hd2ZiQYjpclIhe3SjYnnsbZpifGmxbjDpckBpfW2jbjDEUGQyKGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNm\CC2cnHud4NzcXC2aX;uJI9nKEG6aX6yJIFnfGW{IEKgbJJ{KGK7IGLUMXBEWiCvZYToc4Q> MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF{NUG1Okc,OTlzMkWxOVY9N2F-
DLD1 MXvGeY5kfGmxbjDhd5NigQ>? NG\XR4NKdmS3Y4Tpc44hd2ZiQYjpclIh[WOldX31cIF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iZoLl[UBj\XSjLXPhd4VqdiCuZY\lcJMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MnXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 NVr6WoV7TnWwY4Tpc44h[XO|YYm= NGnIfJFKdmS3Y4Tpc44hd2ZiQYjpclIhe3SjYnnsbZpifGmxbjDpckBpfW2jbjDEUGQyKGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gW451N2KndHGtZ4F{\WmwIIDheIh4[Xl? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTF{NUG1Okc,OTlzMkWxOVY9N2F-
DLD1 MXLGeY5kfGmxbjDhd5NigQ>? MYHJcoR2[3Srb36gc4YhSXirbkKgZYNkfW23bHH0bY9vKGmwIHj1cYFvKESOREGgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hW2W{M{OgdIhwe3Cqb4L5cIF1\WRiYnX0ZU1k[XOnaX6gcIV3\Wy|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NU\UeoNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNlUyPTZpPkG5NVI2OTV4PD;hQi=>
DLD1 NHr5PFlHfW6ldHnvckBie3OjeR?= NG\sWJlKdmS3Y4Tpc44hd2ZiQYjpclIh[WOldX31cIF1cW:wIHnuJIh2dWGwIFTMSFEh[2WubIOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| MoX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMkWxOVYoRjF7MUK1NVU3RC:jPh?=
DLD1 M2Lp[GZ2dmO2aX;uJIF{e2G7 MlPFNUB1dyB{MDD1US=> MXmyOEBpenN? Ml[4TY5pcWKrdHnvckBw\iC2YX7rfZJie2ViaX6gbJVu[W5iRFzENUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIGTDSk1l\XCnbnTlcpQhfHKjboPjdolxfGmxbnHsJIFkfGm4aYT5JIF1KDFidH:gNlAhfU1iYX\0[ZIhOjRiaILzJIJ6KGS3YXygcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV{N{e5Nkc,OjR3Mke3PVI9N2F-
DLD1 NUjMSnB{S3m2b4TvfIlkcXS7IHHzd4F6 NX7CeodrOSC2bzCyNEB2VQ>? M2LtTlExKGSjeYO= NFPxO4pEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFVERzIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHH0JFEhfG9iMkCgeW0hdWWjc4Xy[YQhd25iZHH5JFExKGK7IHPyfZN1[WxidnnvcIV1KHO2YXnubY5o M3jwZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUK3O|kzLz5{NEWyO|c6OjxxYU6=
HT29 NVnrUWI2TnWwY4Tpc44h[XO|YYm= Mki1NlUhfU1? M2TCcVI1KGi{cx?= M1jJTmlvcGmkaYTpc44hd2ZiV370JJNq\26jbHnu[{BqdiCqdX3hckBJXDJ7IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[mW2YT3jZZRmdmmwLX3l[IlifGWmIGTj[k9N\WZidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGG2IEK1JJVOKGGodHXyJFI1KGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUBz\WyjdHn2[UB1dyClb370do9t MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl3MES4PUc,OjR7NUC0PFk9N2F-
HT29 MlO3SpVv[3Srb36gZZN{[Xl? MUCyOUB2VQ>? NXz3N5RGOjRiaILz M3TtWGlvcGmkaYTpc44hd2ZiV370JJNq\26jbHnu[{BqdiCqdX3hckBJXDJ7IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[mW2YT3jZZRmdmmwLX3l[IlifGWmIGTj[k9N\WZidILhcpNkemmydHnvcoFtKGGldHn2bZR6KGG2IEK1JJVOKGGodHXyJFI1KGi{czDifUBlfWGuIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUBz\WyjdHn2[UB1dyClb370do9tKGmwIIDy[ZNmdmOnIH;mJGdUUy1|YnX0ZUBqdmirYnn0c5IhVGmFbB?= MljIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NUC0PFkoRjJ2OUWwOFg6RC:jPh?=
HT29 NY\6cXNNTnWwY4Tpc44h[XO|YYm= M1\5TVI2KHWP NVX0eYl2OjRiaILz NYTSZ4FJUW6qaXLpeIlwdiCxZjDXcpQw[mW2YT3jZZRmdmmwIIPp[45idGmwZzDpckBpfW2jbjDIWFI6KGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHH4bY4zKG2UTlGg[ZhxemW|c3nvckBifCB{NTD1UUBi\nSncjCyOEBpenNiYomgdZVidnSrdHH0bZZmKHKnYXyteIlu\SCSQ2KgZZN{[Xl? NFjmOGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm1NFQ5QSd-MkS5OVA1QDl:L3G+
Assay
Methods Test Index PMID
Western blot E-cadherin / N-cadherin / Snail / Vimentin ; p-Akt / Akt ; Survivin 26450645

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 21 mg/mL
(51.28 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 409.44
Formula

C25H19N3O3

CAS No. 1127442-82-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1C2C=CC1C3C2C(=O)N(C3=O)C4=CC=C(C=C4)C(=O)NC5=CC=CC6=C5N=CC=C6

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy IWR-1-endo | IWR-1-endo supplier | purchase IWR-1-endo | IWR-1-endo cost | IWR-1-endo manufacturer | order IWR-1-endo | IWR-1-endo distributor